Meeting
2023 ASCO Genitourinary Cancers Symposium
Cost-effectiveness of abiraterone acetate for high-risk nnon-metastatic prostate cancer.
Authors
Nataniel Hernan Lester-Coll
University of Vermont Larner College of Medicine, Burlington, VT
Nataniel Hernan Lester-Coll , Shahid Sattar Ahmed , H. James Wallace , Brian L. Sprague , Steven Ades
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Therapeutics
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 358)
DOI
10.1200/JCO.2023.41.6_suppl.358
Abstract #
358
Poster Bd #
M16
Abstract Disclosures
Similar Posters
Poster
2020 Genitourinary Cancers Symposium
Cost-effectiveness of upfront therapeutic options in low-volume de novo metastatic hormone-sensitive prostate cancer.
First Author: Neil Rohit Parikh
Poster
2018 ASCO Annual Meeting
Cost-effectiveness analysis of abiraterone acetate (AA) versus docetaxel (D) for the management of metastatic hormone naïve prostate cancer (mHNPC).
First Author: Chethan Ramamurthy
Poster
2024 ASCO Genitourinary Cancers Symposium
Cost-effectiveness of triplet therapies in metastatic hormone-sensitive prostate cancer used in PEACE-1 and ARASENS.
First Author: Nataniel Hernan Lester-Coll
Poster
2021 Genitourinary Cancers Symposium
High-risk nonmetastatic prostate cancer in the elderly: Does adjuvant chemotherapy affect survival?
First Author: Komal Akhtar